scholarly journals Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

2013 ◽  
Vol 208 (1) ◽  
pp. 32-39 ◽  
Author(s):  
Joel E. Gallant ◽  
Ellen Koenig ◽  
Jaime Andrade-Villanueva ◽  
Ploenchan Chetchotisakd ◽  
Edwin DeJesus ◽  
...  
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Treatment Naïve ◽  
Hiv Type 1

Concurrent CMV and EBV DNAemia Is Significantly Correlated with a Delay in the Response to HAART in Treatment-Naive HIV Type 1-Positive Patients

2007 ◽  
Vol 23 (1) ◽  
pp. 10-18 ◽  
Author(s):  
Simeon H. Panagiotakis ◽  
Giannoula Soufla ◽  
Stavroula Baritaki ◽  
George Sourvinos ◽  
Andreas Passam ◽  
...  
Keyword(s):  
Treatment Naïve ◽  
Hiv Type 1

scholarly journals Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates

2002 ◽  
Vol 46 (4) ◽  
pp. 1067-1072 ◽  
Author(s):  
P. R. Harrigan ◽  
M. D. Miller ◽  
P. McKenna ◽  
Z. L. Brumme ◽  
B. A. Larder
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Tenofovir Disoproxil Fumarate ◽  
Antiretroviral Drug ◽  
Immunodeficiency Virus ◽  
Large Panel ◽  
Treatment Naïve ◽  
Rt Inhibitors ◽  
Hiv 1

ABSTRACT Tenofovir is a nucleotide analogue human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) inhibitor, and its oral prodrug, tenofovir disoproxil fumarate, has recently been approved for the treatment of HIV-1 infection in the United States. The objective of this study was to characterize the in vitro susceptibility profiles of a large panel of clinically derived HIV-1 isolates for tenofovir. The distribution of tenofovir susceptibilities in over 1,000 antiretroviral-naive, HIV-1-infected individuals worldwide was determined using the Virco Antivirogram assay. In addition, phenotypic susceptibilities to tenofovir and other RT inhibitors were determined in a panel of nearly 5,000 recombinant HIV-1 clinical isolates from predominantly treatment-experienced patients analyzed as a part of routine drug resistance testing. Greater than 97.5% of isolates from treatment-naive patients had tenofovir susceptibilities <3-fold above those of the wild-type controls by the Antivirogram. The clinically derived panel of 5,000 samples exhibited a broad range of antiretroviral drug susceptibilities, including 69, 43, and 16% having >10-fold-decreased susceptibilities to at least one, two, and three antiretroviral drug classes, respectively. Greater than 88% of these 5,000 clinical isolates were within the threefold susceptibility range for tenofovir, and >99% exhibited <10-fold-reduced susceptibilities to tenofovir. Decreased susceptibility to tenofovir was not directly associated with resistance to other RT inhibitors; r 2 values of log-log linear regression plots of susceptibility to tenofovir versus susceptibility to other RT inhibitors were <0.4. The results suggest that the majority of treatment-naive and treatment-experienced individuals harbor HIV that remains within the normal range of tenofovir susceptibilities and may be susceptible to tenofovir disoproxil fumarate therapy.

Phylogenetic Diversity and Low Level Antiretroviral Resistance Mutations in HIV Type 1 Treatment-Naive Patients from Cape Town, South Africa

2008 ◽  
Vol 24 (7) ◽  
pp. 1009-1012 ◽  
Author(s):  
Graeme B. Jacobs ◽  
Annette Laten ◽  
Estrelita Janse van Rensburg ◽  
Jochen Bodem ◽  
Benedikt Weissbrich ◽  
...  
Keyword(s):  
South Africa ◽  
Phylogenetic Diversity ◽  
Cape Town ◽  
Resistance Mutations ◽  
Low Level ◽  
Antiretroviral Resistance ◽  
Treatment Naïve ◽  
Hiv Type 1

scholarly journals Deep V3 Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc

2011 ◽  
Vol 53 (7) ◽  
pp. 732-742 ◽  
Author(s):  
Luke C. Swenson ◽  
Theresa Mo ◽  
Winnie W. Y. Dong ◽  
Xiaoyin Zhong ◽  
Conan K. Woods ◽  
...  
Keyword(s):  
Treatment Naïve ◽  
Hiv Type 1

Drug Resistance Mutations of HIV Type 1 Non-B Viruses to Integrase Inhibitors in Treatment-Naive Patients from Sub-Saharan Countries and Discordant Interpretations

2012 ◽  
Vol 28 (9) ◽  
pp. 1157-1160 ◽  
Author(s):  
Marjorie Monleau ◽  
Avelin F. Aghokeng ◽  
Benedicte A. Nkano ◽  
Marie-Laure Chaix ◽  
Martine Peeters, and the AC11/AC12 ANRS Wor
Keyword(s):  
Drug Resistance ◽  
Integrase Inhibitors ◽  
Resistance Mutations ◽  
Drug Resistance Mutations ◽  
Treatment Naïve ◽  
Hiv Type 1 ◽  
Sub Saharan

HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom

2010 ◽  
Vol 15 (7) ◽  
pp. 985-991 ◽  
Author(s):  
Daniella N Chilton ◽  
◽  
Hannah Castro ◽  
Sam Lattimore ◽  
Linda J Harrison ◽  
...  
Keyword(s):  
Drug Resistance ◽  
United Kingdom ◽  
Antiretroviral Treatment ◽  
The United Kingdom ◽  
Treatment Naïve ◽  
Hiv Type 1
Sign in / Sign up

Export Citation Format

Share Document